Daniel J. Brennan - 13 Feb 2025 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
18 Feb 2025, 17:50:51 UTC
Prior SEC filing
14 Feb 2025
Next SEC filing
19 Feb 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Susan Thompson, Attorney-in-Fact

Key filing fact

Daniel J. Brennan filed Form 4 for BOSTON SCIENTIFIC CORP (BSX) on 18 Feb 2025.

Key facts

  • This page summarizes Daniel J. Brennan's Form 4 filing for BOSTON SCIENTIFIC CORP (BSX).
  • 11 reported transactions and 5 derivative rows are listed below.
  • Accepted by SEC: 18 Feb 2025, 17:50.

Change

  • Previous filing in this sequence was filed on 14 Feb 2025.
  • Current net transaction value: -$676,876.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BSX transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+4,362
Change %
+1.8%
Price
$0.000000
Shares after
247,700
Date
14 Feb 2025
Ownership
Direct
Footnotes
F1
BSX transaction

Common Stock

Tax liability

Transaction value
$223,892
Shares
-2,110
Change %
-0.85%
Price
$106.11
Shares after
245,590
Date
14 Feb 2025
Ownership
Direct
BSX transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+4,243
Change %
+1.7%
Price
$0.000000
Shares after
249,833
Date
16 Feb 2025
Ownership
Direct
Footnotes
F1
BSX transaction

Common Stock

Tax liability

Transaction value
$217,738
Shares
-2,052
Change %
-0.82%
Price
$106.11
Shares after
247,781
Date
16 Feb 2025
Ownership
Direct
BSX transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+4,584
Change %
+1.9%
Price
$0.000000
Shares after
252,365
Date
17 Feb 2025
Ownership
Direct
Footnotes
F1
BSX transaction

Common Stock

Tax liability

Transaction value
$235,246
Shares
-2,217
Change %
-0.88%
Price
$106.11
Shares after
250,148
Date
17 Feb 2025
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BSX transaction Derivative

Restricted Stock Units

Award

Transaction value
$0
Shares
+8,950
Change %
Price
$0.000000
Shares after
8,950
Date
13 Feb 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
8,950
Exercise price
Footnotes
F1, F2
BSX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+23,031
Change %
Price
$0.000000
Shares after
23,031
Date
13 Feb 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
23,031
Exercise price
$106.14
Footnotes
F3
BSX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-4,362
Change %
-33%
Price
$0.000000
Shares after
8,725
Date
14 Feb 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,362
Exercise price
Footnotes
F1, F4
BSX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-4,243
Change %
-50%
Price
$0.000000
Shares after
4,243
Date
16 Feb 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,243
Exercise price
Footnotes
F1, F5
BSX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-4,584
Change %
-100%
Price
$0.000000
Shares after
0
Date
17 Feb 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
4,584
Exercise price
Footnotes
F1, F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Footnote F2

Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.

Footnote F3

Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.

Footnote F4

Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.

Footnote F5

Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

Footnote F6

Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .